EphA2 is a transmembrane tyrosine kinase receptor, a member of the tyrosine kinase receptor (RTKs) superfamily. Like other tyrosine kinases, the EphA2 molecule can be divided into three domains, the extracellular ligand binding domain, the intracellular tyrosine kinase active functional domain and the transmembrane domain. EphA2 is involved in the development of the nervous system and the development of the vascular system. At the same time, studies have shown that high expression of EphA2 can be found in breast cancer, colon cancer, prostate cancer, lung cancer, cervical cancer, ovarian cancer and other tissues .This product is a second-generation CAR lentiviral expression plasmid targeting EphA2, which can be used for in vivo and in vitro pharmacodynamic experiments.

Product name: Lenti-EF1a-CD33-2nd-CAR

Promoter: EF1a [1]

Intracellular co-activation signal: 4- 1 BB /CD3Zata

Resistance gene: Amp

Tag: EGFRt [2]



1. Compared with the CMV promoter, EF1a can be continuously expressed in immune cells, so it can significantly extend the expression of CAR in T cells.

2.  EGFRt intercepts domain III and domain IV of wild-type EGFR. This truncated EGFRt has no intracellular signal and will not transmit other signals to T cells . At the same time, these two domains are cetuximab Recognizing the epitope and expressing the epitope on T cells can not only be used as CAR-T screening markers, but also add a safety switch for clinical research. Related flow cytometry antibodies can be inquired ( iCareAb, CAT# IAB001A )